Abstract
Increasing amount of data considering polymorphism, splice variants and various affinity states of betaadrenoceptors has resulted in a new range of opportunities for enantiopure beta-adrenergic and beta-adrenolytic drug discovery and continuous development of reliable high-throughput screening procedures enabling tissue specific pharmacological evaluation of these drugs. Design and fast pharmacological profiling of single enantiomeric molecules combining beta-adrenoceptor affinity with other pharmacophores is also still challenging ability. As the use of chiral stationary phases in HPLC has particularly benefited from results of supramolecular chemistry, this review summarises recent achievements provided by this technique in deciphering of enatiorecognition phenomena affecting pharmacological selectivity of beta-adrenergics and beta-adrenolytics and modifying the efficiency of currently proposed beta-adrenoceptortargeted therapies. Detailed characteristic of chiral separation performance of these drugs in the range of available supramolecular HPLC systems has also been presented.
Keywords: Beta-blockers, beta-agonists, chiral drug screening, supramolecular devices, recognition mechanisms, supramolecular chirality, dosage formulations, body fluid samples
Current Drug Discovery Technologies
Title: Supramolecular Systems-Based HPLC for Chiral Separation of Beta-Adrenergics and Beta-Adrenolytics in Drug Discovery Schemes
Volume: 4 Issue: 4
Author(s): Imran Ali, Afzal Hussain, Hassan Y. Aboul-Enein and Grzegorz Bazylak
Affiliation:
Keywords: Beta-blockers, beta-agonists, chiral drug screening, supramolecular devices, recognition mechanisms, supramolecular chirality, dosage formulations, body fluid samples
Abstract: Increasing amount of data considering polymorphism, splice variants and various affinity states of betaadrenoceptors has resulted in a new range of opportunities for enantiopure beta-adrenergic and beta-adrenolytic drug discovery and continuous development of reliable high-throughput screening procedures enabling tissue specific pharmacological evaluation of these drugs. Design and fast pharmacological profiling of single enantiomeric molecules combining beta-adrenoceptor affinity with other pharmacophores is also still challenging ability. As the use of chiral stationary phases in HPLC has particularly benefited from results of supramolecular chemistry, this review summarises recent achievements provided by this technique in deciphering of enatiorecognition phenomena affecting pharmacological selectivity of beta-adrenergics and beta-adrenolytics and modifying the efficiency of currently proposed beta-adrenoceptortargeted therapies. Detailed characteristic of chiral separation performance of these drugs in the range of available supramolecular HPLC systems has also been presented.
Export Options
About this article
Cite this article as:
Ali Imran, Hussain Afzal, Aboul-Enein Y. Hassan and Bazylak Grzegorz, Supramolecular Systems-Based HPLC for Chiral Separation of Beta-Adrenergics and Beta-Adrenolytics in Drug Discovery Schemes, Current Drug Discovery Technologies 2007; 4 (4) . https://dx.doi.org/10.2174/157016307783220576
DOI https://dx.doi.org/10.2174/157016307783220576 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Selective Serotonin Reuptake Inhibitors (SSRIs): Therapeutic Drug Monitoring and Pharmacological Interactions
Current Medicinal Chemistry Fibrate-Associated Adverse Effects Beyond Muscle and Liver Toxicity
Current Pharmaceutical Design Stem Cell Therapy for the Treatment of Acute Myocardial Infarction and Chronic Ischemic Heart Disease
Current Pharmaceutical Biotechnology Colchicine in Neurosurgery
Current Pharmaceutical Design Molecular Basis of Cardioprotection by Erythropoietin
Current Molecular Pharmacology Atypical Antipsychotics: Pharmacokinetics, Therapeutic Drug Monitoring and Pharmacological Interactions
Current Medicinal Chemistry Patent Selections :
Recent Patents on Cardiovascular Drug Discovery Class III Antiarrhythmics and Phenytoin: Teratogenicity Due to Embryonic Cardiac Dysrhythmia and Reoxygenation Damage
Current Pharmaceutical Design Mechanism and Development of Modern General Anesthetics
Current Topics in Medicinal Chemistry How to Recognize Epicardial Origin of Ventricular Tachycardias?
Current Cardiology Reviews Does Caffeine Affect Cardiovascular Responses?
Vascular Disease Prevention (Discontinued) The Effect of SEX/Gender on Cardiovascular Pharmacology
Current Pharmaceutical Design Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) New Approaches in the Diagnosis of Atherosclerosis and Treatment of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery HCN Channel as Therapeutic Targets for Heart Failure and Pain
Current Topics in Medicinal Chemistry Antiplatelet Therapy in Acute Coronary Syndromes. Evidence Based Medicine
Current Pharmaceutical Design The Role of Transcription Factors in the Formation of an Arrhythmogenic Substrate in Congestive Human Heart Failure
Current Medicinal Chemistry Influence of Gender on C-Reactive Protein, Fibrinogen, and Erythrocyte Sedimentation Rate in Obstructive Sleep Apnea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Glucose Metabolism and Insulin Resistance in Sepsis
Current Pharmaceutical Design Advanced Therapies For End-Stage Heart Failure
Current Cardiology Reviews